Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria

被引：0
|
作者：
Akihiro Tomita
Yukari Shirasugi
Takahiko Ito
Hisashi Tsurumi
Tomoki Naoe
机构：
[1] Nagoya University Graduate School of Medicine,Department of Hematology and Oncology
[2] Tokai University Hospital,Department of Hematology and Oncology
[3] Gifu Social Insurance Hospital,Department of Hematology
[4] Gifu University Graduate School of Medicine,First Department of Internal Medicine
来源：
Annals of Hematology | 2012年 / 91卷
关键词：
Hemolytic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Eculizumab; Hemoglobinuria; Intravascular Hemolysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1139 / 1141
页数：2
相关论文
共 50 条
  • [41] Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria
    Hamburger, LP
    Bernnstein, A
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1936, 192 : 301 - 316
  • [42] THERAPY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    FREEMAN, H
    NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (23): : 1253 - 1254
  • [43] RESPONSE TO ECULIZUMAB COMBINED WITH CYCLOSPORINE AFTER FAILURE OF ECULIZUMAB MONOTHERAPY IN 2 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Deldicque, M.
    Knoops, L.
    Van den Neste, E.
    Delannoy, A.
    HAEMATOLOGICA, 2013, 98 : 585 - 586
  • [44] MODELING AND SIMULATIONS OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) PATIENTS
    Lathia, C.
    Kassir, N.
    Mouksassi, M. S.
    Jayaraman, B.
    Marier, J. F.
    Bedrosian, C. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S2 - S2
  • [45] Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis
    Pagliuca, S.
    Risitano, A. M.
    De Fontbrune, F. S.
    Robin, M.
    Iori, A. P.
    Marotta, S.
    Michonneau, D.
    Villate, A.
    Desmier, D.
    Socie, G.
    De latour, R. P.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 105 - 107
  • [46] Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis
    S Pagliuca
    A M Risitano
    F S De Fontbrune
    M Robin
    A P Iori
    S Marotta
    D Michonneau
    A Villate
    D Desmier
    G Socié
    R P De Latour
    Bone Marrow Transplantation, 2018, 53 : 105 - 107
  • [47] Safety and efficacy of eculizumab with concomitant erythropoietin therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Mojcik, C. F.
    Young, N. S.
    Luzzatto, L.
    Socie, G.
    Hillmen, P.
    Brodsky, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Fanconi syndrome and chronic kidney disease in paroxysmal nocturnal hemoglobinuria: effect of eculizumab therapy
    Moumas, Eric
    Bridoux, Frank
    Leroy, Fannie
    Belmouaz, Simohamed
    Randriamalala, Edouard
    Desport, Estelle
    Dreyfus, Brigitte
    Delbes, Sebastien
    Quellard, Nathalie
    Touchard, Guy
    CLINICAL NEPHROLOGY, 2012, 78 (04) : 316 - 321
  • [49] Vaccination of patients with paroxysmal nocturnal hemoglobinuria under eculizumab treatment
    Rodriguez-Garcia, Juan
    Fernandez-Santos, Rafael
    Antonio Garcia-Erce, Jose
    MEDICINA CLINICA, 2012, 138 (14): : 640 - 641
  • [50] Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria
    Schrezenmeier, Hubert
    Hoechsmann, Britta
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (01) : 7 - 16
12345